Concord Medical Services Holdings (FRA:C2C) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


FRA:C2C Concord Medical Services Holdings Ltd FRA:C2C
51 GF Score
Price €6.25
GF Value €9.81
! 6 Warning Signs
View Full Analysis

What is Concord Medical Services Holdings Research & Development?

Concord Medical Services Holdings FRA:C2C 51 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:C2C with a GF Score™ of 51/100 and a GF Value™ of €9.81. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Concord Medical Services Holdings's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Concord Medical Services Holdings  (FRA:C2C) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Concord Medical Services Holdings Research & Development Related Terms

Concord Medical Services Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Concord Medical Services Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Medical Services Holdings Research & Development Chart

Concord Medical Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Concord Medical Services Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:C2C
51GF Score
Concord Medical Services Holdings Ltd FRA:C2C
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Medical Services Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Concord Medical Services Holdings (FRA:C2C) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Concord Medical Services Holdings and its competitors.
Is Concord Medical Services Holdings' Research & Development too high?
Concord Medical Services Holdings' current Research & Development is €0.00 Mil. Overall, Concord Medical Services Holdings has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Concord Medical Services Holdings' Research & Development compare to CCEL and GBCS?
Concord Medical Services Holdings' Research & Development of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Concord Medical Services Holdings and its competitors. Concord Medical Services Holdings's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Medical Services Holdings stock overvalued right now?
Concord Medical Services Holdings (FRA:C2C) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €9.81, compared to a current price of €6.25 — trading 36.3% below its estimated fair value. The current Research & Development is €0.00 Mil. Concord Medical Services Holdings' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Concord Medical Services Holdings (FRA:C2C), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Medical Services Holdings (FRA:C2C) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Medical Services Holdings stock appears to be undervalued. The current stock price of €6.25 is trading 36.3% below its estimated GF Value™ of €9.81.

Key valuation signals for FRA:C2C:

  • Research & Development: €0.00 Mil
  • GF Value™: €9.81 vs. price of €6.25 (36.3% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the FRA:C2C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Medical Services Holdings Business Description

Other Exchanges CCM:USA
Address Hanwei Plaza Building, No. 7 Guanghua Road, Room A1-A5, 26th Floor, East Area, Chaoyang District, Beijing, CHN, 100020
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
51GF Score

Get the complete analysis for FRA:C2C

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.25
Price
€9.81
GF Value